Int J Immunopathol Pharmacol. 2012 Jan-Mar;25(1):25-30. doi: 10.1177/039463201202500104.
Chronic inflammatory rheumatic diseases are associated with an increased risk of cardiovascular (CV) atherosclerotic events. The inflammatory state, which is the hallmark of chronic rheumatic diseases, is the important driving force for accelerated atherogenesis. Since the control of traditional risk factors alone is insufficient in reducing the risk, much attention has been directed towards the potential use of statins. Statins, a family of drugs that suppress cholesterol biosynthesis by inhibiting the hydroxymethyl glutaryl coenzyme A reductase, have been shown to significantly reduce CV-related morbidity and mortality. In addition to lower lipid levels, several non-lipid lowering pleiotropic effects, including anti-inflammatory and immunomodulatory activities, make statins potential therapeutic agents in chronic rheumatic diseases. However, lipid metabolism in chronic rheumatic diseases is complex, since inflammatory states can induce alterations in lipid levels and function, so that cholesterol target levels from general guidelines may not be adequate in chronic inflammatory rheumatic diseases. Larger trials are needed to refine the precise benefits and health-utility associated with this therapy.
慢性炎症性风湿性疾病与心血管（CV）动脉粥样硬化事件的风险增加有关。炎症状态是慢性风湿性疾病的标志，是加速动脉粥样硬化形成的重要驱动力。由于仅控制传统危险因素不足以降低风险，因此人们非常关注他汀类药物的潜在用途。他汀类药物是一类通过抑制羟甲基戊二酰辅酶 A 还原酶抑制胆固醇生物合成的药物，已被证明可显著降低与心血管相关的发病率和死亡率。除了降低血脂水平外，他汀类药物还具有几种非降脂的多效作用，包括抗炎和免疫调节作用，使其成为慢性风湿性疾病的潜在治疗药物。然而，慢性风湿性疾病中的脂质代谢较为复杂，因为炎症状态可引起脂质水平和功能的改变，因此一般指南中的胆固醇目标水平在慢性炎症性风湿性疾病中可能不够充分。需要更大规模的试验来细化与这种治疗相关的精确益处和健康效用。
